Formulary Chapter 2: Cardiovascular system - Full Chapter
02.08.01
Parenteral anticoagulants
Argatroban
Restricted
Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013)
Provider notes
NMUH:
Non-formulary
RFL:
As per restrictions above
Haemophilia recommendation only
RNOH:
Requires Haematologist approval. See restriction above.
UCLH:
Restricted to consultant haematologists. For patients with severe renal impairment (CrCl<30ml/min)
WH approval:
Non-formulary
02.08.01
Heparin
Heparin sodium (Anticoagulation)
Formulary
NOTE: There is more than one monograph for this medicine, click hereto search for formulary status and its use for other indications.
This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.